New diabetes drug tested in patients with kidney problems
NCT ID NCT05374343
First seen May 07, 2026 · Last updated May 24, 2026 · Updated 4 times
Summary
This early-stage study looked at how the drug rongliflozin behaves in 32 people with type 2 diabetes who have normal, mildly, or moderately reduced kidney function. Researchers measured drug levels in the blood and how much sugar was passed in urine after a single dose. The goal was to understand safety and effectiveness across different kidney health levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ping Feng
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.